Compare STAA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | KURA |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | 1211 | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | STAA | KURA |
|---|---|---|
| Price | $23.35 | $10.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $24.56 | ★ $25.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $230,591,000.00 | $104,029,000.00 |
| Revenue This Year | N/A | $138.16 |
| Revenue Next Year | $21.97 | $66.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.50 | $5.41 |
| 52 Week High | $30.81 | $12.49 |
| Indicator | STAA | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 48.79 |
| Support Level | $22.90 | $9.68 |
| Resistance Level | $26.18 | $11.28 |
| Average True Range (ATR) | 1.46 | 0.56 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 8.86 | 36.50 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.